HIV Transmission Risks and Evidence‑Based Prevention Strategies

Per‑Act Transmission Probabilities by Exposure Route

Blood transfusion with contaminated blood transmits HIV in approximately 95 % of exposures (Clinical Infectious Diseases, 2009) 1.
Sharing needles among people who inject drugs results in a 0.67 % (≈1 in 150) per‑act transmission risk (Clinical Infectious Diseases, 2009) 2.
Occupational needlestick injuries carry a 0.3–0.36 % (≈1 in 300) risk; prompt post‑exposure prophylaxis (PEP) reduces this risk by about 81 % (CDC MMWR, 1998) 3.
Receptive anal intercourse has the highest sexual‑act risk, estimated at 0.5–10 % (≈1 in 10 to 1 in 1,600) (Clinical Infectious Diseases, 2009) 1.
Receptive vaginal intercourse (male‑to‑female) carries a 0.05–0.5 % risk (≈1 in 200 to 1 in 2,000) (Clinical Infectious Diseases, 2009) 2.
Insertive vaginal intercourse (female‑to‑male) carries a 0.03–0.14 % risk (≈1 in 700 to 1 in 3,000) (Clinical Infectious Diseases, 2009) 2.
Mother‑to‑child transmission without antiretroviral therapy occurs in about 25 % of births (≈1 in 4) (Clinical Infectious Diseases, 2009) 1.
With effective antiretroviral therapy and appropriate interventions, vertical transmission falls to <2 % (≈92 % risk reduction) (Clinical Infectious Diseases, 2009) 2.

Each 10‑fold increase in plasma HIV viral load in the source partner raises heterosexual transmission risk by roughly 2.5‑fold (CDC MMWR, 2003) 4.
Concurrent sexually transmitted infections in either partner markedly increase transmission probability by fostering mucosal inflammation and higher viral shedding (Clinical Infectious Diseases, 2009) 1.
Acute (primary) HIV infection in the source partner, characterized by very high viral loads, substantially elevates transmission risk (CDC MMWR, 2003) 5.
Consistent condom use is a highly effective barrier method that markedly lowers sexual transmission risk (CDC MMWR, 2003) 6.

High‑risk heterosexual contact accounts for roughly 80 % of HIV cases among women and 16 % among men (Clinical Infectious Diseases, 2009) 1.
Injection drug use contributes to about 19 % of HIV cases in women and 12 % in men (Clinical Infectious Diseases, 2009) 2.

Genital secretions can contain HIV even when plasma viral load is undetectable; thus, transmission is still possible (CDC MMWR, 2003) 4.
Interruptions of antiretroviral therapy lead to viral rebound and heightened transmission risk (CDC MMWR, 2003) 5.
Antiretroviral therapy does not replace risk‑reduction behaviors; condom use remains essential (CDC MMWR, 2003) 6.
Published per‑act risk estimates represent population averages and may be misleading when applied to individual circumstances (CDC MMWR, 2003) 4.
The only certain methods to prevent sexual HIV transmission are abstinence or exclusive sexual partnership with a confirmed HIV‑negative partner (CDC MMWR, 2003) 5.
For people who inject drugs, certainty of prevention is achieved only by abstaining from injection or never sharing injection equipment (CDC MMWR, 2003) 6.

The Centers for Disease Control and Prevention recommends that receptive anal intercourse carries the highest per-act risk of HIV transmission, with estimates ranging from 1 in 10 to 1 in 1600 exposures 7
The per-act transmission probability for receptive anal intercourse is 0.5-3% (1 in 10 to 1 in 1600), representing the highest sexual transmission risk, according to the Centers for Disease Control and Prevention 7, 8
The per-act transmission probability for receptive vaginal intercourse is 0.1-0.2% (1 in 200 to 1 in 2000) for male-to-female vaginal intercourse, as recommended by the Centers for Disease Control and Prevention 7, 8
The per-act transmission probability for insertive vaginal intercourse is 1 in 700 to 1 in 3000 for female-to-male vaginal intercourse, according to the Centers for Disease Control and Prevention 7

The presence of sexually transmitted infections (STDs) in either partner dramatically increases HIV transmission probability through mucosal inflammation and increased viral shedding, as stated by the Centers for Disease Control and Prevention 7, 9
High viral load in the HIV-positive partner significantly increases per-act transmission risk, according to the Centers for Disease Control and Prevention 7, 8
The presence of trauma or bleeding during intercourse further elevates risk, as recommended by the Centers for Disease Control and Prevention 8
Lack of male circumcision increases receptive partner risk in heterosexual transmission, according to the American Urological Association 10
Antiretroviral therapy in the HIV-positive partner reduces transmission risk by approximately 96% when viral suppression is achieved, as stated by the American Medical Association 10
Pre-exposure prophylaxis (PrEP) in the HIV-negative partner provides substantial protection, according to the Centers for Disease Control and Prevention 10

Men who have sex with men (MSM) practicing receptive anal intercourse face the highest HIV acquisition risk and should receive quarterly HIV testing and immediate PrEP consideration, as recommended by the Centers for Disease Control and Prevention 9, 11
The presence of recurrent bacterial STIs in individuals practicing receptive anal intercourse creates a synergistic increase in HIV transmission risk requiring immediate intervention, according to the Centers for Disease Control and Prevention 9, 11

Post-exposure prophylaxis (PEP) should be initiated within 72 hours (ideally within 24 hours) following high-risk exposure, using a 28-day course of combination antiretroviral therapy, as recommended by the Centers for Disease Control and Prevention 8, 12
Pre-exposure prophylaxis (PrEP) should be offered immediately to individuals with recurrent bacterial STI diagnosis or ongoing high-risk sexual practices, according to the Centers for Disease Control and Prevention 9, 11
Comprehensive STI screening every 3-6 months at all exposure sites (pharynx, rectum, urethra) is essential for high-risk individuals, as stated by the Centers for Disease Control and Prevention 9, 11